510(k) K260214
K260214 is an FDA 510(k) premarket notification submitted by Diagnostica Stago, Inc. for the device "STA® - Liquid Anti-Xa". The FDA issued a decision of Substantially Equivalent on Sep 24, 2026. The device falls under product code KFF (Assay, Heparin), a Class II device regulated under 21 CFR 864.7525. Diagnostica Stago, Inc. has 21 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Sep 24, 2026
- Date Received
- Jan 23, 2026
- Clearance Type
- Special
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Assay, Heparin
- Device Class
- Class II
- Regulation Number
- 864.7525
- Review Panel
- HE
- Submission Type
- 510(k)